More than 740 medications are known to carry some risk of hearing damage, ranging from common over-the-counter pain relievers to powerful chemotherapy drugs. The risk varies enormously: some cause temporary ringing that fades within days, while others can destroy inner ear cells permanently. Knowing which drug categories pose the greatest threat, and what makes certain people more vulnerable, can help you have better conversations with your care team.
Platinum-Based Chemotherapy Drugs
Cisplatin is the most consistently ototoxic medication in clinical use. It damages the cochlea, the snail-shaped structure in your inner ear responsible for converting sound into nerve signals. Between 40% and 80% of adults treated with cisplatin develop significant permanent hearing loss, and at least 50% of children do. The hearing loss typically starts at high frequencies, meaning you might first notice difficulty understanding speech in noisy rooms or miss high-pitched sounds like doorbells, before it progresses to lower frequencies with continued treatment.
Because of this high rate of damage, clinical guidelines recommend a baseline hearing test no later than 24 hours after the first treatment, with repeat testing before every subsequent dose. Follow-up tests are also recommended immediately after treatment ends and again at 3 and 6 months, since hearing can continue to decline even after the drug is stopped.
Aminoglycoside Antibiotics
Aminoglycosides, a class of antibiotics that includes gentamicin and amikacin, are used for serious infections like sepsis and complicated urinary tract infections. These drugs enter the sensory hair cells of the inner ear through channels at the tips of the tiny hair-like structures that detect sound. Once inside, the channels act like a one-way valve, trapping the drug and causing it to accumulate to much higher concentrations than in surrounding tissue.
Inside the hair cell, the antibiotic triggers a chain reaction. It combines with iron to generate highly reactive molecules called free radicals, which damage cell membranes. It also disrupts the cell’s energy-producing machinery, starving the cell and eventually triggering a programmed self-destruct sequence. The result is permanent loss of hair cells, which do not regenerate in humans. High-frequency hearing is usually affected first.
Monitoring guidelines recommend a baseline hearing test within 72 hours of starting treatment, with follow-up testing every two to three days or at least weekly. A specialized test that measures sounds naturally produced by healthy hair cells can detect damage before you notice any change in hearing yourself.
A Genetic Factor Worth Knowing About
A specific inherited mutation in mitochondrial DNA, known as A1555G, makes certain people dramatically more vulnerable to aminoglycoside hearing loss. Carriers of this mutation can develop severe, irreversible deafness after even a single course of treatment. Among deaf individuals with a history of aminoglycoside use, 15% to 30% carry this mutation. Because it is passed through the maternal line, if one woman in a family carries it, all of her children and all maternal relatives may carry it too. Genetic testing before aminoglycoside treatment is increasingly available and can prevent catastrophic outcomes.
Loop Diuretics
Loop diuretics like furosemide are commonly prescribed for fluid retention related to heart failure, kidney disease, and high blood pressure. They can cause tinnitus and hearing impairment, but in most cases the effect is reversible once the drug is stopped or the dose is lowered. The risk climbs when the drug is given intravenously at a fast rate, at high doses, or alongside other hearing-damaging drugs like aminoglycosides.
The FDA label for injectable furosemide specifically warns that ototoxicity is linked to rapid injection, severe kidney impairment, doses higher than recommended, and combination therapy with other ototoxic drugs. Premature infants are particularly vulnerable; those born before 31 weeks who receive more than 1 milligram per kilogram per day may reach blood levels associated with ear toxicity.
Aspirin and Other Pain Relievers
Aspirin at high doses is a well-established cause of tinnitus and temporary hearing loss. The threshold sits well above the dose most people take for a headache or heart protection. In clinical studies, daily doses of 6 grams (roughly eighteen standard 325 mg tablets) produced tinnitus in 66% of participants within the first week. Even at lower but still elevated doses of up to 4.8 grams per day, about 0.8% of patients reported tinnitus and 0.3% reported noticeable hearing reduction.
The good news is that aspirin-related hearing changes are almost always reversible. In studies tracking recovery, hearing returned to normal within 48 hours to three weeks after stopping the drug. This reversibility distinguishes aspirin from drugs like cisplatin or aminoglycosides, where the damage is typically permanent. Other nonsteroidal anti-inflammatory drugs can behave similarly at high doses, though they are less studied.
Antimalarial Drugs
Quinine and chloroquine, used to treat and prevent malaria, can damage both the hearing and balance systems of the inner ear. Symptoms include tinnitus, vertigo, a feeling of fullness in the ear, and unsteadiness while walking. Unlike aspirin, hearing loss from antimalarials tends to be permanent. A systematic review of chloroquine and hydroxychloroquine cases found that only one study documented any improvement in hearing after stopping the drug, and even that recovery was incomplete.
There is a narrow window: if the drug is stopped early enough, some lesions in the inner ear may not yet be irreversible. In one reported case, considerable hearing improvement appeared after 10 days off the medication, with “socially acceptable” hearing returning after two more weeks. But in three other studies reviewed, the hearing loss was permanent. The key factor appears to be catching the damage early, which is difficult because inner ear injury can be subtle at first.
Erectile Dysfunction Medications
In 2007, the FDA required manufacturers of sildenafil (Viagra), tadalafil (Cialis), and vardenafil (Levitra) to add warnings about sudden sensorineural hearing loss to their labels. This followed 29 case reports with a strong association between the drugs and hearing loss, along with additional reports of tinnitus and dizziness. The hearing loss in these cases was sudden, sometimes occurring within hours of taking the medication, and often affected one ear more than the other. While this side effect is rare, it is serious enough that the FDA considered the evidence compelling.
Why Some People Are More Vulnerable
Kidney function plays a central role in how quickly your body clears most ototoxic drugs. When the kidneys are impaired, medications like aminoglycosides and furosemide stay in the bloodstream longer and reach higher concentrations, increasing the chance they’ll damage the inner ear. People with chronic kidney disease face a double risk: they often need the very drugs most likely to harm hearing (antibiotics for infections, diuretics for fluid management), and their kidneys are less able to flush those drugs out efficiently.
Other factors that raise risk include taking multiple ototoxic drugs at the same time, receiving higher cumulative doses, being very young or very old, and having pre-existing hearing loss. The genetic mutation discussed earlier in the aminoglycoside section is another major vulnerability that can turn a routine antibiotic course into a life-altering event.
What Hearing Monitoring Looks Like
If you’re starting a medication with known ototoxic potential, your care team may order a baseline hearing test before treatment begins. This gives them a reference point. During treatment, repeat tests can catch early changes at high frequencies before they become noticeable in everyday conversation. One type of test, which measures faint sounds naturally emitted by healthy outer hair cells, is especially useful because it can detect damage at a stage when it might still be limited by adjusting the drug.
After treatment ends, hearing should be tested immediately and again at 3 and 6 months, since some drugs continue to cause damage even after the last dose. If you notice new ringing, muffled sound, or difficulty following conversations during any medication course, report it promptly. Early detection gives your doctor the best chance to switch drugs or adjust doses before the loss becomes irreversible.